International Stem Cell Corporation (OTCBB:ISCO) today announced that
Co-Chairman Ken Aldrich and President and Chief Operating Officer Kurt
May will be presenting at the 4th Annual LD MICRO Growth Conference in
Los Angeles on Thursday, December 8, 2011 at 2:30 p.m. Pacific. The
conference is being held at the Luxe Sunset Boulevard Hotel.
LD Micro founder Chris Lahiji stated, "We are excited to host over 100
companies for the first time in our history. What makes us especially
proud, however, are all the interesting companies from our own backyard
in Southern California, such as International Stem Cell, that are
presenting this year."
About International Stem Cell Corporation
International Stem Cell Corporation is focused on the therapeutic
applications of human parthenogenetic stem cells (hpSCs) and the
development and commercialization of cell-based research and cosmetic
products. ISCO's core technology, parthenogenesis, results in the
creation of pluripotent human stem cells from unfertilized oocytes
(eggs). hpSCs avoid ethical issues associated with the use or
destruction of viable human embryos. ISCO scientists have created the
first parthenogenic, homozygous stem cell line that can be a source of
therapeutic cells for hundreds of millions of individuals of differing
genders, ages and racial background with minimal immune rejection after
transplantation. hpSCs offer the potential to create the first true stem
cell bank, UniStemCell™. ISCO also produces and markets specialized
cells and growth media for therapeutic research worldwide through its
subsidiary Lifeline Cell Technology, and cell-based skin care products
through its subsidiary Lifeline Skin Care. More information is available
at www.internationalstemcell.com.
To subscribe to receive ongoing corporate communications, please click
on the following link: http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0.
Forward-looking Statements
Statements pertaining to anticipated developments, potential sales
growth and other opportunities for the company and its subsidiaries,
along with other statements about the future expectations, beliefs,
goals, plans, or prospects expressed by management constitute
forward-looking statements. Any statements that are not historical fact
(including, but not limited to statements that contain words such as
"will," "believes," "plans," "anticipates," "expects," "estimates,")
should also be considered to be forward-looking statements.
Forward-looking statements involve risks and uncertainties, including,
without limitation, risks inherent in the development and/or
commercialization of potential products and the management of
collaborations, regulatory approvals, need and ability to obtain future
capital, application of capital resources among competing uses, and
maintenance of intellectual property rights. Actual results may differ
materially from the results anticipated in these forward-looking
statements and as such should be evaluated together with the many
uncertainties that affect the company's business, particularly those
mentioned in the cautionary statements found in the company's Securities
and Exchange Commission filings. The company disclaims any intent or
obligation to update forward-looking statements.
International Stem Cell Corporation
Kenneth
C. Aldrich, Co-Chairman
760-940-6383
kaldrich@intlstemcell.com
or
LHA
Don
Markley
310-691-7100
dmarkley@lhai.com